Krystal Biotech, Inc. KRYS Accretion on marketable securities
Accretion on marketable securities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept krys:AccretionExpenseNet.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accretion on marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accretion on marketable securities?
- Krystal Biotech, Inc. (KRYS) reported accretion on marketable securities of -$576K in Q1 2026.
- How has Krystal Biotech, Inc.'s accretion on marketable securities changed year-over-year?
- Krystal Biotech, Inc.'s accretion on marketable securities decreased by 27.2% year-over-year, from -$453K to -$576K.
- What is the long-term trend for Krystal Biotech, Inc.'s accretion on marketable securities?
- Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s accretion on marketable securities has grown at a -9.4% compound annual growth rate (CAGR), from $670K to -$498K.
- What does accretion on marketable securities mean?
- The non-cash interest income recognized as the value of discounted securities grows toward maturity.
- How do you interpret accretion on marketable securities?
- An increase reflects higher interest-bearing asset holdings, signaling a conservative cash management strategy.
- How does accretion on marketable securities compare across companies?
- Common for companies with large cash reserves invested in debt securities.